Thomas Van Looy - Search Results

Year	Number of Results
2011	1
2012	2
2013	1
2014	4
2015	1
2016	1
2019	1
2020	1
2022	1
2024	0

1

In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor.

Schöffski P, Gebreyohannes Y, Van Looy T, Manley P, Growney JD, Squires M, Wozniak A. Schöffski P, et al. Among authors: van looy t. Biomedicines. 2022 May 13;10(5):1135. doi: 10.3390/biomedicines10051135. Biomedicines. 2022. PMID: 35625872 Free PMC article.

2

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.

Gebreyohannes YK, Schöffski P, Van Looy T, Wellens J, Vreys L, Cornillie J, Vanleeuw U, Aftab DT, Debiec-Rychter M, Sciot R, Wozniak A. Gebreyohannes YK, et al. Among authors: van looy t. Mol Cancer Ther. 2016 Dec;15(12):2845-2852. doi: 10.1158/1535-7163.MCT-16-0224. Epub 2016 Oct 24. Mol Cancer Ther. 2016. PMID: 27777285

3

Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor.

Remmerie B, van den Boer M, Van Looy T, Wynant I, Rusch S, Huntjens D, De Meulder M, Stevens M. Remmerie B, et al. Among authors: van looy t. Adv Ther. 2020 Jan;37(1):578-591. doi: 10.1007/s12325-019-01162-7. Epub 2019 Dec 12. Adv Ther. 2020. PMID: 31832988

4

Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.

Quattrone A, Wozniak A, Dewaele B, Floris G, Vanspauwen V, Van Looy T, Schöffski P, Rutkowski P, Sciot R, Debiec-Rychter M. Quattrone A, et al. Among authors: van looy t. Mod Pathol. 2014 Nov;27(11):1510-20. doi: 10.1038/modpathol.2014.53. Epub 2014 Apr 18. Mod Pathol. 2014. PMID: 24743220 Free article.

5

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.

Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, Donsky R, Morgan JG, Mayeda M, Fletcher JA, Schöffski P, Lyons J, Thompson NT, Wallis NG. Smyth T, et al. Among authors: van looy t. Mol Cancer Ther. 2012 Aug;11(8):1799-808. doi: 10.1158/1535-7163.MCT-11-1046. Epub 2012 Jun 19. Mol Cancer Ther. 2012. PMID: 22714264 Free PMC article.

6

Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.

Van Looy T, Wozniak A, Floris G, Sciot R, Li H, Wellens J, Vanleeuw U, Fletcher JA, Manley PW, Debiec-Rychter M, Schöffski P. Van Looy T, et al. Clin Cancer Res. 2014 Dec 1;20(23):6071-82. doi: 10.1158/1078-0432.CCR-14-1823. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316817

7

The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.

Floris G, Sciot R, Wozniak A, Van Looy T, Wellens J, Faa G, Normant E, Debiec-Rychter M, Schöffski P. Floris G, et al. Among authors: van looy t. Clin Cancer Res. 2011 Sep 1;17(17):5604-14. doi: 10.1158/1078-0432.CCR-11-0562. Epub 2011 Jul 7. Clin Cancer Res. 2011. PMID: 21737509

8

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models.

Li H, Wozniak A, Sciot R, Cornillie J, Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter M, Schöffski P. Li H, et al. Among authors: van looy t. Transl Oncol. 2014 Dec;7(6):665-71. doi: 10.1016/j.tranon.2014.09.007. Transl Oncol. 2014. PMID: 25500074 Free PMC article.

9

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.

Van Looy T, Wozniak A, Floris G, Li H, Wellens J, Vanleeuw U, Sciot R, Debiec-Rychter M, Schöffski P. Van Looy T, et al. Transl Oncol. 2015 Apr;8(2):112-8. doi: 10.1016/j.tranon.2015.02.004. Transl Oncol. 2015. PMID: 25926077 Free PMC article.

10

A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.

Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, Wellens J, Vermaelen P, Deroose CM, Fletcher JA, Debiec-Rychter M, Schöffski P. Floris G, et al. Among authors: van looy t. Clin Cancer Res. 2013 Feb 1;19(3):620-30. doi: 10.1158/1078-0432.CCR-12-2853. Epub 2012 Dec 11. Clin Cancer Res. 2013. PMID: 23231951 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year